CORE in the News

Howie and Harlan are joined by Yale neonatologist Sarah Taylor to discuss our growing understanding of breastfeeding, including the active role that infants play in shaping the composition of breast milk. Harlan discusses the rapid growth of Hims & Hers Health, which provides treatment and medication over the internet; Howie reports on the promising initial results from a pilot program in North Carolina that seeks to reduce healthcare costs by providing support in non-medical areas like food security and housing. 

A small number of people report chronic symptoms after receiving COVID-19 shots. A new study provides clues for further research.

Most of health care companies’ net income goes to shareholders, according to a research letter recently published in JAMA Internal Medicine.

Dr. Arjun Venkatesh, chair of emergency medicine at Yale School of Medicine and Yale Medicine talks about the newly approved non-opioid pain medication approved by the Food and Drug Administration. Plus, new research about AI’s ability to spot heart conditions and treat seizures post-stroke.

AI-assisted testing in emergency rooms could lead to early diagnosis of cardiomyopathies, Yale-led research finds.

Yale researchers developed an artificial intelligence (AI) tool that can identify individuals at high risk of developing heart failure using electrocardiogram (ECG) images. The new tool enables earlier identification of heart failure, potentially reducing hospitalizations and premature death, the researchers said.

In a new report, scientists at the Yale School of Public Health warn that smoke from the California wildfires can exacerbate cardiovascular problems. They also say the compound extreme weather events that preceded the fires represent a new era in public health in which climate change-driven disasters create new challenges for protecting population health.

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options to reach the market and help address a shortage.

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options to reach the market and help address a shortage.